<DOC>
	<DOCNO>NCT00927758</DOCNO>
	<brief_summary>To examine post-dose change exhale Nitric Oxide ( eNO ) follow treatment inhale Advair subject chronic stable asthma define Global Initiative Asthma ( GINA ) guideline .</brief_summary>
	<brief_title>Pilot Study Examine Post-Dose Changes Exhaled Nitric Oxide ( eNO ) Following Treatment With Fluticasone Propionate ( FP ) /Salmeterol ( SAL ) Combination Product Advair</brief_title>
	<detailed_description />
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>must able speak , read , understand English exhale Nitrous Oxide level must great equal 60 ppb screen great equal 55 ppb Visits 2 , 9 , 16 must history least 6 month chronic , stable asthma except presence asthma , subject must general good health past present history experience allergic reaction medication use study subject must receive ongoing regular treatment inhale corticosteroid subject must ragweed allergy subject must recent history respiratory infection least 1 month prior screen end study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>